Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FS-1502 with serplulimab and chemotherapy in HER2-expressing advanced gastric cancer
CTR20222196Phase 2Terminated
- Sponsor
- Fosun Pharma
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of caxmotabart entudotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fosun Pharma. Started Nov 2022; status: terminated.
02
Drugs
caxmotabart entudotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20222196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222196.